Profile of patients undergoing third line anti-retroviral therapy

Authors

  • Dhileeban Maharajan P. Department of Medicine, Regional Institute of Medical Sciences, Imphal, Manipur, India
  • T. Jeetenkumar Singh Department of Medicine, Regional Institute of Medical Sciences, Imphal, Manipur, India
  • S. Bhagyabati Devi Department of Medicine, Regional Institute of Medical Sciences, Imphal, Manipur, India
  • H. Rebachandra Singh Department of Microbiology, Regional Institute of Medical Sciences, Imphal, Manipur, India
  • Dipul Rudra Paul Department of Medicine, Regional Institute of Medical Sciences, Imphal, Manipur, India
  • Janani L. Department of Community Medicine, Regional Institute of Medical Sciences, Imphal, Manipur, India

DOI:

https://doi.org/10.18203/2349-3933.ijam20203605

Keywords:

ART, Darunavir, Failure, HIV, Raltegravir, Ritonavir, Third-line

Abstract

Background: India has the third largest human HIV epidemic in the world. The advent of antiretroviral drug began a revolution in the management of HIV. Recent studies have shown that an increasing number of patients experiencing virologic failure on second line Antiretroviral therapy and require third line ART.

Methods: This prospective cohort study was conducted in Regional Institute of Medical Sciences, Imphal for a period of two years, to study the clinical, immunological, and virological profile of patients undergoing third line Antiretroviral therapy and to study the early immuno-virological response to third line Antiretroviral therapy.

Results: Mean CD4 count before third line ART initiation was 95.90±111.85 cells/μl with 60% of them had CD4 count <100 cells/μl. The mean CD4 count improved significantly (p<0.005) to 246.70±123.78 cells/μl after six months and 340.70±198.57 cells/μl after one year of the therapy. At the time of initiation of third line ART, none of the patients had viral load <150copies/ml while 60% of the population had viral load >100000 copies/ml. After one year of third line ART, 80 % of the patients showed viral suppression (VL<150copies/ml). At the end of one year, the improvement in CD4 count comparing to the Viral load was significant in those who showed viral suppression (VL<150 copies/ml).

Conclusions: This study showed significant improvement in the CD4 count and viral suppression with third line medication without any major clinical adverse effect.

Metrics

Metrics Loading ...

References

World Health Organization. HIV/AIDS, 2020. Available at: http://www.who.int/features/qa/ 71/en.html. Accessed November 12, 2016.

National AIDS Control Organization. Antiretroviral Therapy Guidelines for HIV-Infected Adults and Adolescents May 2013. Available at: http://naco.gov.in/treatment.html. Accessed January 28, 2015.

National AIDS Control Organization. National Guidelines on Second-line and Alternative First-line ART for Adults and Adolescents May 2013. Available at: http://naco.gov.in/treatment.html. Accessed January 28, 2015.

National AIDS Control Organization. HIV estimation 2017 report. Available at: http://naco.gov.in/treatment.html. Accessed January 28, 2019.

National AIDS Control Organization. National Technical Guidelines on ART October 2018. Available at: http://naco.gov.in/treatment.html. Accessed November 14, 2018.

HIV.gov: What Are HIV and AIDS?. Available from: https://www.hiv.gov/hiv-basics/overview/about-hiv-and-aids/what-are-hiv-and-aids.15 May 2017. Accessed 30 July, 2017.

Centers for Disease Control and Prevention (CDC). About HIV/AIDS. Available from: https://www.cdc.gov/hiv/basics/whatishiv.html. 2019. Accessed 9 September, 2019.

Division of AIDS (DAIDS). Table for Grading the Severity of Adult and Pediatric Adverse Events Version 2.0 November 2014. Available from: https://rsc.niaid.nih.gov/sites/default/files/daids-ae-grading-table-v2-nov2014.pdf. Accessed 30 July, 2017.

Cesar C, Shepherd BE, Jenkins CA, Ghidinelli M, Castro JL, Veloso VG, et al. Use of third line antiretroviral therapy in Latin America. PLoS One. 2014;9(9):1–6.

Khan S, Das M, Andries A, Deshpande A, Mansoor H, Saranchuk P, et al. Second-line failure and first experience with third-line antiretroviral therapy in Mumbai, India. Glob Health Action. 2014;7(1):1-10.

Eron JJ, Young B, Cooper DA, Youle M, DeJesus E, Andrade-Villanueva J, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010;375(9712):396–407.

Pujari SN, Makane A, Lodha A, Bele V, Joshi K. Short-term effectiveness and safety of third-line antiretroviral regimens among patients in western India. J Acquir Immune Defic Syndr. 2014;65(2):2013–5.

Meintjes G, Dunn L, Coetsee M, Hislop M, Leisegang R, Regensberg L, et al. Third-line antiretroviral therapy in Africa: Effectiveness in a Southern African retrospective cohort study. AIDS Res Ther. 2015;12(1):1–12.

Deshwal R, Arora S. Clinical, immunological, and virological outcomes in HIV patients on raltegravir-based salvage therapy. IJSTD. 2019;4(1):1–5.

Grinsztejn B, Hughes MD, Ritz J, Salata R, Mugyenyi P, Hogg E, et al. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study. Lancet HIV. 2019;3018(19).

Moorhouse M, Maartens G, Venter WDF, Moosa MY, Steegen K, Jamaloodien K, et al. Third-Line Antiretroviral Therapy Program in the South African Public Sector: Cohort Description and Virological Outcomes. J Acquir Immune Defic Syndr. 2019;80(1):73–8.

Levison JH, Orrell C, Gallien S, Kuritzkes DR, Fu N, Losina E, et al. Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa. PLoS One. 2012;7(3):3–7.

Saravanan S, Madhavan V, Balakrishnan P, Smith DM, Solomon SS, Sivamalar S, et al. Darunavir is a good third-line antiretroviral agent for HIV type 1-infected patients failing second-line protease inhibitor-based regimens in South India. AIDS Res Hum Retroviruses. 2013;29(3):630–2.

Chimbetete C, Katzenstein D, Shamu T, Spoerri A, Estill J, Egger M, et al. HIV-1 drug resistance and third-line therapy outcomes in patients failing second-line therapy in Zimbabwe. Infect Dis. 2018;5(2):1–8.

Antinori A, Lazzarin A, Uglietti A, Palma M, Mancusi D, Termini R, et al. Efficacy and safety of boosted darunavir-based antiretroviral therapy in HIV-1-positive patients: Results from a meta-analysis of clinical trials. Sci Rep. 2018;8(1):45-54.

Downloads

Published

2020-08-25

How to Cite

Maharajan P., D., Singh, T. J., Devi, S. B., Singh, H. R., Paul, D. R., & L., J. (2020). Profile of patients undergoing third line anti-retroviral therapy. International Journal of Advances in Medicine, 7(9), 1394–1399. https://doi.org/10.18203/2349-3933.ijam20203605

Issue

Section

Original Research Articles